{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/27485413"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "ility to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "eurekalert.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/223335523"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/27485413"] } } }
